ClinicalTrials.gg
Not yet recruitingNCT07106645Updated Aug 6, 2025

Intermittent Theta Burst Transcranial Magnetic Stimulation of the Right Parietal Lobe in Anorexia Nervosa

An interventional study of Active iTBS and Sham stimulation in Anorexia Nervosa, sponsored by University of Padova. Not yet recruiting at 1 site in Italy. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-08-06.

Sponsored by University of Padova · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
34
Allocation
Randomized
Ages
18 Years and older
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 31 studies in Anorexia Nervosa with a site in Italy — 11 open to participants now, 12 under way, none of them phase 3. Anorexia Nervosa · Italy.

Planned enrollment
11th of 12
34 · median 74
Started
2025
with 4 others
No phase
12 of 31
6 open now
Primary completion
2027-01
later than 8 of 11 live
Registered
26th of 31
by date
Lead sponsor
2 of 31
University of Padova

Among the 31 studies in Anorexia Nervosa with a site in Italy, this one is the 11th largest by planned enrollment of the 12 interventional ones that give a count, is one of 5 that started in 2025, is one of 12 with no phase, reaches primary completion later than 8 of the 11 other live ones, and was the 26th registered.

Anorexia Nervosa

471 studies on the registry are indexed under Anorexia Nervosa; 127 are open to participants now.

Browse Anorexia Nervosa studies →

Open to participants now

11 of the 31 studies in Anorexia Nervosa with a site in Italy are open now. Recruiting first, the newest first:

5 more — sign in →

All 11 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 82 Anorexia Nervosa studies recruiting now, 18 (22%) set no upper age limit and 60 (73%) stop at 75 or younger; 48 take children under 18; 26 take healthy volunteers.

This study: 18 Years and older · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 31 studies in Anorexia Nervosa with a site in Italy, or all of them as a file.
02

Study summary

Anorexia Nervosa is a psychiatric disorder characterized by high rates of chronicity, significant societal costs, and one of the highest mortality rates among psychiatric illnesses. Despite therapeutic advances, treatment outcomes remain poor, with high relapse rates and full recovery achieved in only 50% of cases.

Recent cognitive, behavioral, and neuroimaging studies suggest that Anorexia Nervosa may involve dysfunction in a posterior parietal network responsible for multisensory integration. This network plays a pivotal role in bodily self-representation and the modulation of environment-body interactions, and may therefore be directly implicated in two core symptoms of the disorder: distorted body image representation and dietary restriction. Given these insights, Transcranial Magnetic Stimulation (TMS) - an established neuromodulation technique with proven efficacy in various psychiatric disorders - emerges as a promising investigational intervention. The aim of this study is to evaluate the feasibility and therapeutic efficacy of a protocol of intermittent Theta Burst Stimulation (iTBS) targeting the right posterior parietal lobe in patients with Anorexia Nervosa. The active iTBS protocol will be compared to a sham (placebo) stimulation as a control condition.

Read the detailed description

Patients with anorexia nervosa will be recruited from the Eating Disorder Unit of Padova Hospital. Inclusion criteria will be: (1) current diagnosis of anorexia nervosa according to DSM-5 criteria; (2) 18 years or older; (3) failure of an outpatient treatment cycle lasting at least 3 months. Exclusion criteria will be: (1) Presence of significant neurological comorbidities or severe/unstable systemic diseases, (2) Diastolic blood pressure \<60 mmHg or heart rate \<60 bpm, (3) diagnosis of psychosis or substance abuse disorders, (4) history of hypomanic/manic episodes (5) Current suicidal ideation, (6) known contraindications to TMS (epilepsy, head trauma with loss of consciousness, severe/frequent headaches, cochlear implants, pacemakers, pregnancy, metallic implants, implanted neurostimulators)

Each patient will be randomly assigned to one of two conditions: active iTBS or sham stimulation

iTBS protocol: Patients in this condition will undergo 20 sessions of iTBS, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Intermittent theta burst stimulation will involve the delivery of triplets of pulses at 50 Hz, repeated at 5 Hz, at 100% of the individual motor threshold.

Sham Stimulation: Patients in this condition will undergo the same protocol (20 sessions of TMS), with the only difference being the use of a sham coil, which produces the same sound as the real coil without generating a magnetic field

Patients in both conditions will complete a baseline assessment (Day 0), an end-of-treatment assessment (Week 4), and a follow-up assessment (4 months after the end of treatment).

All the assessments will include:

Clinical interview with a psychiatrist who is blind to the stimulation condition. During the interview, the clinician will also record the patients' weight and height to calculate Body Mass Index (BMI).

Depression Anxiety Stress Scales - 21 items (DASS-21): a validated 21-item scale for assessing depression, anxiety, and stress.

Eating Disorders Inventory (EDI-I): a validated 64-item scale for assessing eating disorder psychopathology.

Body Attitude Questionnaire: a validated questionnaire on body dissatisfaction and body perception.

Wisconsin Card Sorting Task (WCST): assessment of set-shifting abilities.

Rey-Osterrieth Complex Figure Test: assessment of central coherence.

03

Conditions studied

  • Anorexia Nervosa

Keywords

  • psychiatry
  • eating disorders
  • neurostimulation
  • TMS
  • Transcranial Magnetic Stimulation
  • Anorexia Nervosa
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inclusion criteria will be: (1) current diagnosis of anorexia nervosa according to criteria; (2) 18 years or older; (3) failure of an outpatient treatment cycle lasting at least 3 months

Exclusion criteria

Exclusion Criteria:

  • Exclusion criteria will be: (1) Presence of significant neurological comorbidities or severe/unstable systemic diseases, (2) Diastolic blood pressure \<60 mmHg or heart rate \<60 bpm, (3) diagnosis of psychosis or substance abuse disorders, (4) history of hypomanic/manic episodes (5) Current suicidal ideation, (6) known to TMS (epilepsy, head trauma with loss of consciousness, severe/frequent headaches, cochlear implants, pacemakers, pregnancy, metallic implants, implanted neurostimulators)
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

DSM diagnostic criteria

The American Psychiatric Association’s manual of mental health diagnoses. DSM-5 (2013, revised as DSM-5-TR in 2022) replaced DSM-IV, and some studies still name the older edition. “Meets DSM criteria for …” means diagnosed by that edition’s diagnostic criteria, usually by a clinician in an interview.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
34 participants (estimated)

Study arms

  • Experimental
    active iTBS

    Patients in this condition will undergo 20 sessions of iTBS over the right posterior parietal lobe, one per day for 20 consecutive working days (4 weeks)

    Device: Active iTBS

  • Active comparator
    sham stimulation

    Patients in this condition will undergo 20 sessions of sham stimulation over the right posterior parietal lobe, one per day for 20 consecutive working days (4 weeks)

    Device: Sham stimulation

Interventions

  • DeviceActive iTBS

    Patients in this condition will undergo 20 sessions of iTBS, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Intermittent theta burst stimulation will involve the delivery of triplets of pulses at 50 Hz, repeated at 5 Hz, at 100% of the individual motor threshold.

  • DeviceSham stimulation

    Patients in this condition will undergo 20 sessions of sham stimulation, one per day for 20 consecutive working days (4 weeks). Each visit will last approximately 20 minutes, including preparation, 3 minutes of stimulation, and debriefing. The coil position will be identified using a neuronavigation system based on each participant's MRI. Sham stimulation will be identical to active stimulation, with the only difference being the use of a sham coil, which produces the same sound as the real coil without generating a magnetic field

06

What researchers measure

Primary outcomes

  1. Change from baseline in Body Mass Index (BMI)

    BMI will be calculated from patients' height and weight using the formula: weight (kg) divided by height (m) squared.

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

Secondary outcomes

  1. Change from baseline in depression, anxiety and stress

    The DASS-21 is a validated self-report instrument consisting of three subscales assessing symptoms of depression, anxiety, and stress. The score of each subscale can range from 0 to 42, with higher scores representing higher levels of psychopathology.

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

  2. Change from baseline in eating disorder psychopathology

    The EDI-I is a 64-item self-report scale for the assessment of eating disorder psychopathology. The scale comprises 8 subscales (drive for thinness, bulimia, body dissatisfaction, ineffectiveness, perfectionism, interpersonal distrust, interoceptive awareness, maturity fears). Total score ranges from 64 to 384 and greater scores indicate greater psychopathology

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

  3. Change from baseline in body dissatisfaction and perception

    The Body Attitude Questionnaire is a 26 item self-report scale for the assessment of body dissatisfaction and perception. The questionnaire comprises 3 subscales (body satisfaction, body concern, body distortion). Total score ranges from 26 to 130 and higher scores indicate greater body dissatisfaction and concern.

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

  4. Change from baseline in cognitive flexibility

    The Wisconsin Card Sorting Task is a well-validated neuropsychological task for the assessment of cognitive flexibility. As outcome variables, the number of perseverative responses and perseverative errors will be taken into account.

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

  5. Change from baseline in central coherence

    The Rey-Osterrieth complex figure is a well-validated neuropsychological test for the assessment of visuospatial functioning and memory. As outcome variables, the indexes of central coherence in both the copy and memory phase will be taken into account.

    Time frame: Day 0 (baseline), Week 4 (end of treatment), Week 20 (4-month follow-up)

Other outcomes

  1. feasibility and acceptability of iTBS treatment

    percentage of patients who will complete the intervention

    Time frame: 4 weeks

07

Study locations

1 site
08

References and documents

Publications

  • Meregalli V, Gentili S, Menardi A, Vallesi A, Olivo D, Manara R, Serino A, Risso G, Sambataro F, Favaro A, Collantoni E. Individualized targeting of the posterior parietal cortex with intermittent theta burst stimulation in anorexia nervosa: a randomized, double-blind, sham-controlled protocol. Front Neurosci. 2026 Jan 21;19:1733280. doi: 10.3389/fnins.2025.1733280. eCollection 2025. PubMed 41648851 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Sep 2025; primary completion for Jan 2027, 16 months later.

Of 149 non-industry interventional studies with no phase under Anorexia Nervosa, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 63. This study's planned 16 months is below that.

Counting every sponsor, half of 149 studies reached it within 43 months; a quarter within 24 and three quarters within 63.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2025
First posted
Aug 6, 2025
StartEst.
Sep 1, 2025
Primary completionEst.
Jan 15, 2027
CompletionEst.
Sep 1, 2027
Last update
Aug 6, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 6, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07106645
Collaborators
Azienda Ospedaliera di Padova
Responsible party
Sponsor
First posted
Aug 6, 2025
Start date
Sep 1, 2025 (estimated)
Primary completion
Jan 15, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Aug 6, 2025

Study contacts

Enrico Collantoni, MD, PhD
Contact
enrico.collantoni@unipd.it
+390498218175
Valentina Meregalli, PhD
Contact
valentina.meregalli@unipd.it
Enrico Collantoni, MD, PhD
principal investigator · University of Padova

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion